HZ/su VACCINE

Phase 3Vaccine

GSK

HZ/su VACCINE is one of 54 biologic programs targeting Kidney Transplant. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney TransplantActive, not recruiting

Herpes ZosterActive, not recruiting

Kidney TransplantPhase 3

Active, not recruiting

Herpes ZosterPhase 3

Active, not recruiting

Competition

Competitive Landscape

476 competitors in Kidney Transplant

#DrugCompanyPhaseTrials

Nulojix

Bristol-Myers Squibb

Preclinical

16 2

Simulect

Novartis

Preclinical

15 3

HZ/su VACCINE

GSK

Phase 3

1 4

Zinbryta

Roche

Preclinical

6 5

Zemplar

AbbVie

Preclinical

2 6

Cysteine Hydrochloride

Novartis

Preclinical

1 7

Sensipar

Amgen

Preclinical

1 8

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

1 9

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

4 10

Jardiance

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Active, not recruiting

Herpes Zoster

NCT05371080

Clinical

Trials by Indication[1]

Herpes Zoster5 trials

Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds

Completed·UUniversity of Colorado, Denver·Phase 1·NCT02114333·160 enrolled

A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults

Active, not recruiting· GSK logo

GSK·Phase 3·NCT05371080·3,038 enrolled

A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults

Completed· Pfizer logo

Pfizer·Phase 3·NCT06890416·526 enrolled

Show 2 more trials

A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults

Completed· GSK logo

GSK·Phase 3·NCT05966090·530 enrolled

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older

Completed· GSK logo

GSK·Phase 3·NCT03439657·913 enrolled

Kidney Transplant1 trial

A Study to Test GlaxoSmithKline's (GSK) Herpes Zoster (HZ) Subunit Vaccine's Long-term Immune Response in Previously Vaccinated Kidney Transplant Adults and Then to Test if 2 Additional Doses of the Vaccine Are Safe and Able to Generate an Immune Response

Completed· GSK logo

GSK·Phase 3·NCT04176939·68 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for HZ/su VACCINE. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HZ/su VACCINE compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HZ/su VACCINE. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 3[1]
Company: GSK

HZ/su VACCINE

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Herpes Zoster5 trials

Kidney Transplant1 trial

References

Drug Info

Quick Facts

Related News